Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Affibody Announces Option Exercise by Biotest

Solna, Sweden, December 4, 2018. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a portfolio of innovative drug projects, today announced that its partner Biotest, a Germany-based biotherapeutic company, has exercised an option under the two companies’ ongoing collaboration.“Biotest has finalized the research phase of the research license and option agreement we originally signed in 2015 and based on the preclinical results decided to exercise its option. Biotest now receives exclusive rights for further development and commercialization of an innovative new

Biovica establishes office in Boston

Biovica opens an office in Boston, the first office in the US. Pontus Nobréus, Business Development Director, will be heading up the office and will be based in Boston from 1st of January 2019.The office will be located in west Boston. The location is chosen since Boston is an important biotech hub in the US with Biovica collaboration partners, such as Dana Farber Cancer Institute, in the nearby area. USA is the single largest market for Biovica and, most important market. Biovica has previously started a US subsidiary in order to operate in the United States. It is important for us that

Breakthrough for Magic-as-a-Service in North America and general strengthening of cash flows

Realfiction Holding AB (“Realfiction”) announces that the company has received four individual Magic-as-a-Service (MaaS) orders in North America covering Mixed Reality solutions for four premium events in New York, Miami, Las Vegas and Toronto. With these orders, Realfiction and MaaS are gaining significant momentum in North America.With its MaaS concept, Realfiction is offering a full-service Mixed Reality solution including everything from rental and installation of the hardware to original 3D content with periodic over-the-air updates for a fixed monthly fee. It has already gained

OnDosis and Recipharm partner to advance a novel treatment regimen for ADHD

Swedish life science company, OnDosis, and global contract development and manufacturing organisation (CDMO), Recipharm, have entered into an agreement for the formulation development of an ADHD treatment for the US market.[Recipharm20OnDosis] The new treatment for the management of ADHD will be developed by Recipharm’s Centre of Excellence in Oral Solids and will leverage OnDosis’ proprietary technology which integrates oral drugs in form of micro units and individualised dosing, in a handheld device. The advantages are simplified titration, more accurate dosing and the ability to track

MTG backs premiere gaming and interactive entertainment start-ups

MTG has funded 11 fast-growing companies  that bring strategic value to the Group’s owned and operated esports and online gaming businesses. This makes MTG one of the most active investors in the gaming sector, with a broad portfolio of content, tools and live experiences.· MTG has invested in 11 high-potential US and European gaming businesses since announcing its dedicated gaming fund in November 2017 · Investees include innovative online gaming and esports companies, as well as virtual reality experiences · The investment fund complements

OnDosis and Recipharm partner to advance a novel treatment regimen for ADHD

Swedish life science company, OnDosis, and global contract development and manufacturing organisation (CDMO), Recipharm, have entered into an agreement for the formulation development of an ADHD treatment for the US market. The new treatment for the management of ADHD will be developed by Recipharm’s Centre of Excellence in Oral Solids and will leverage OnDosis’ proprietary technology which integrates oral drugs in form of micro units and individualised dosing, in a handheld device. The advantages are simplified titration, more accurate dosing and the ability to track dosing and

Strong interest in sales start of affordable row houses in Nedersta

The recent start of sales by Bonava of row houses in Nedersta, Västerhaninge south of Stockholm, was met with strong interest from customers. As many as 25 homes were reserved shortly after the first viewing. This phase of the development comprises a total of 58 row houses and semi-detached houses of between 92 and 123 square metres.- I am delighted with the strong interest shown in our row houses in Nedersta. The project is further evidence that we are successful in our strategic direction. Our defined building systems and efficient internal processes enable us to offer affordable row

STRONG RESULT IN LINE WITH OUTLOOK

AUGUST 2018–OCTOBER 2018 · Revenue: MSEK 12,678 (11,644) · Earnings before tax and nonrecurring items: MSEK 842 (1,054) · EBT: MSEK 809 (657) · Net income for the period: MSEK 640 (490) · Earnings per common share: SEK 1.60 (1.22) · SAS expects to deliver a positive result before tax and nonrecurring items in fiscal year 2019  COMMENTS BY THE PRESIDENT AND CEO OF SAS: More than 30 million passengers traveled with SAS during fiscal year 2018, which is more than any other previous year. This shows that our strategy continues to deliver results.  For further

Skanska sells Bergskvadraten development project in Norrköping, Sweden, for about SEK 490 M

Skanska divests Bergskvadraten development project in Norrköping, Sweden, to Rikshem for about SEK 490 M. The block contains 101 apartments with garage and 72 nursing homes. The project is developed by Skanska Sweden. The divestment will be recorded in the business streams Commercial Property Development and Residential Development in the fourth quarter 2018. The transfer is scheduled for the third quarter 2021.The construction contract, worth about SEK 300 M, was awarded to Skanska Sweden and booked in Q3, 2018. The houses will be built with between two and seven floors with split-level

Samhällsbyggnadsbolaget i Norden AB presents new financial and operational targets

In conjunction with Samhällsbyggnadsbolaget i Norden (publ)’s (”SBB”) Capital Market Day, the company today presents new financial and operational goals adopted by the Board. The goals are presented with a view to give the capital market an updated picture of the company's future direction. SBB's new financial targets (previous levels are given in brackets below): -          Generate growth in net asset value per ordinary share, excluding dividends on ordinary shares, to average at least 12 percent per year over a 5-year period (unchanged) -          Loan to value ratio below 55

Storytel launching service in Bulgaria

In announcing its purchase of Bulgarian audio-book service D&D Factory on September 19th, Storytel made public its intention of providing its streaming service in that country. Today Storytel’s goes online in Bulgaria, its fifteenth market.“Streaming services for film and music are making strong headway in Bulgaria, and we’re interested in getting involved in that development at an early stage. We have a long list of titles, everything from bestsellers to classics to non-fiction, in both Bulgarian and English,” says Stefan Tegenfalk, Head of Expansion. “We’re constantly increasing our

Additional product patent in the United States for HyNap-Dasa

STOCKHOLM, SWEDEN – December 4, 2018. Xspray Pharma AB (Nasdaq First North: XSPRAY) (“Xspray” or the “Company”) announces that the United States Patent and Trademark Office (USPTO) today has granted a new patent in the United States to Xspray. The new patent, US 10,143,683, covers the pharmaceutical composition of Xspray’s lead product candidate, HyNap-Dasa. This is Xspray’s third product patent in the US which is Xspray’s main market. The new patent will expireJanuary 11, 2033.“This new patent approval in our most important market further confirms our innovative development work. Together

Stora Enso and startup Sulapac have joined forces to develop renewable and biodegradable straws

STORA ENSO OYJ PRESS RELEASE 4 December 2018 at 9.00 EETStora Enso and Sulapac continue to combat the global problem of plastic waste by launching a demo for sustainable drinking straws at Slush 2018, a leading startup event that gathers 20 000 tech enthusiasts from around the world. The demo, which targets production on an industrial scale, is designed to replace traditional plastic straws with renewable ones. The straws are based on Sulapac’s biocomposite material – made of wood and natural binders – designed to be recycled via industrial composting and biodegrade in marine environments.

Kindred selects Kambi for NJ sports betting platform

Kindred has agreed with Kambi to extend its current agreement on sports betting products to also include New Jersey. The extension demonstrates the strong partnership between Kindred and Kambi.Kindred Group (previously Unibet Group) has agreed to sign an addendum to the current contract the Group has with Kambi. The addendum will give Kindred access to Kambi’s sports betting platform in New Jersey. This agreement, together with the already communicated agreement with SG Digital, will allow Kindred to offer customers in New Jersey a full range of first class sports betting and casino

Biotage acquires PhyNexus, Inc. and strengthens its position in lab-scale purification of biomolecules

Stockholm – Biotage AB (publ) (Biotage), (Nasdaq Stockholm: BIOT.ST) has today entered into an agreement to acquire all outstanding shares in the privately held company PhyNexus, Inc. (PhyNexus) based in California, US, for a total purchase price of approx. USD 21.5 million (corresponding to approx. SEK 195 million[1]) financed through a combination of newly issued shares in Biotage and existing cash at hand. The acquisition is expected to strengthen Biotage’s position as a separations company within the growing biomolecule arena. Biotage will be able to provide its global customers an

Raisio plc's renewed dividend policy

Raisio Oyj, Stock Exchange Release, 4.12.2018, 8.31 am. Finnish time RAISIO PLC’S RENEWED DIVIDEND POLICYThe Board of Directors has renewed the company’s dividend policy. Raisio plc aims to pay an annual dividend of 50 - 100 per cent of earnings per share (EPS) for its continuing operations. In addition, the Board of Directors may propose an extra dividend to be distributed. The payment of dividends under the dividend policy is subject to the condition that the payment does not compromise the company’s financial position or the achievement of strategic objectives. Raisio plc

Skanska invests EUR 24 M, about SEK 250 M, in the second phase of office project in Łódź, Poland

Skanska has invested EUR 24 M, about SEK 250 M, in the second phase of Brama Miasta, an office development in Łódź, Poland. The second phase with a total leasable area of around 13,600 square meters will consist of one building 15 stories high.Brama Miasta is Skanska’s third office development in Łódź. This two-building complex, to be delivered in two phases, will offer a total leasable area of around 41,400 square meters. The project is expected to receive LEED Gold certification, as well as a “Building without barriers” certificate. The new office development will be situated in the

Raisio's new strategy for 2019 - 2021

Raisio plc, Stock Exchange Release, 4 December 2018 at 8.30 am. Finnish time RAISIO’S NEW STRATEGY FOR 2019 - 2021 Raisio’s Board of Directors has approved the new strategy of the company for 2019 - 2021. Raisio focuses on healthy food and aims to be an innovative and increasingly international brand house. Strategic growth both organically and through acquisitions is Raisio’s key target. The goal-oriented Responsibility Programme is a solid part of the strategy. Raisio’s new Healthy Growth Strategy is based on two strong pillars. On the one hand, Raisio will continue to invest in

Handheld promotes Robert Broström to Director of Service and Support

[Lidköping, Sweden, December 4, 2018] Handheld Group , a leading manufacturer of rugged mobile computers has promoted Robert Broström to Director of Service and Support. Additionally, in an effort to further strengthen the Handheld customer experience and service quality, this function has been added to the Handheld management team. As Director of Service and Support, Robert Broström has global responsibility for the Handheld service and support departments  serving customers and resellers around the

Nordic Nanovector: Additional preclinical studies with CD37-targeting radioimmunotherapies for B-cell malignancies presented at ASH

Oslo, Norway, 4 December 2018 Nordic Nanovector ASA (OSE: NANO) notes that two new poster presentations from preclinical studies with CD37-targeting radioimmunotherapies were made at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition (1-4 December 2018 in San Diego, CA, USA). These posters were presented in addition to the results of the Phase 1/2 trial of Betalutin® (177Lu-satetraxetan-lilotomab) in patients with relapsed/refractory indolent non-Hodgkin’s lymphoma – see separate announcement. The posters are as follows: Abstract 4422 Abstract title:

Data presented at ASH support emapalumab as an innovative, targeted therapeutic option for primary HLH

Swedish Orphan Biovitrum AB (publ) (Sobi™)  and Novimmune SA  are presenting data from the pivotal phase 2/3 clinical study of emapalumab-lzsg in primary haemophagocytic lymphohistiocytosis (HLH) as part of the late-breaking abstract session at the 60th Annual Meeting of the American Society of Hematology (ASH), taking place 1-4 December 2018, in San Diego. “Primary HLH is an aggressive hyper-inflammatory syndrome that can quickly become fatal if not treated. This study demonstrated that emapalumab treatment induced rapid and sustained

Amendment of previously announced press release Sedana Medical AB (publ), Sedana Medical’s nomination committee appointed

In the previously announced press release the following text was included: This information is such that Sedana Medical AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons above, on 3 December 2018 at 17:00 pm (CET). This text should not have been included and below is the amended press release in full.Press release December 03, 2018. Sedana Medical’s nomination committee appointed Sedana Medical AB (publ) today publish that in accordance with the resolution of

Axactor SE – Announcement regarding the relocation to Norway and potential trade restrictions for certain shares related thereto

Oslo, December 3, 2018 – As previously announced, Axactor SE (“Axactor” or the “Company”), have filed for relocation of its registered office from Sweden to Norway in order to reduce the burden of administrative expenses and achieve a more efficient group structure. The expected day for completion of the relocation is December 20, 2018 at which point, the Company will be removed out of the company register at the Sweden Companies Registration Office (Bolagsverket) and instead registered with the Norwegian Companies Register (Foretaksregisteret i Brønnøysund). As set-out in the

Borr Drilling Limited (BDRILL) – Purchase of own shares

Borr Drilling Limited (the “Company”) has today purchased 200,000 of its own shares at an average price of NOK 28.7281 per share. The share purchase has been carried out in connection with the share repurchase program announced by the Company on 28 August 2018. After this transaction the Company holds 5,898,572 of its own shares in treasury. 3 December 2018 Hamilton, Bermuda This information is subject to disclosure requirements pursuant to Sections 4-2 and 5-12 of the Norwegian Securities Trading Act.

There are no items matching the current filter
There are no more items matching the current filter
Back to top